Opexa Therapeutics Grants Merck Serono Option to Multiple Sclerosis T-cell Therapy
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 2 (Table of Contents)
Published: 16 Feb-2013
DOI: 10.3833/pdr.v2013.i2.1898 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Opexa Therapeutics has granted Merck Serono a licence option to its personalised T-cell therapy Tcelna™ (imilecleucel-T), which may be exercised prior to or on completion of the ongoing Phase IIb trial of the immunotherapy for secondary progressive multiple sclerosis (MS)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS